No Data
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Express News | Piper Sandler maintains the target price of Alnylam Pharmaceuticals at $296.00.
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
U.S. stock market opportunities | Transitioning to nasdaq? palantir has surged nearly three times this year, with stock prices reaching new highs; the cryptos craze continues! The exchange Coinbase skyrocketed nearly 10% overnight.
The Ministry of Finance has canceled the tax refund! The cancellation of tax refunds for aluminum products has caused aluminum prices to soar, and alcoa's stock price has reached a new high in a year.
No Data
No Data